ixazomib extends pfs in the tourmaline-mm1 trial
Published 8 years ago • 390 plays • Length 6:52Download video MP4
Download video MP3
Similar videos
-
3:55
ixazomib benefit persists despite prior therapy in tourmaline-mm1 subset analysis
-
4:19
tourmaline-mm3 and 4: ixazomib as maintenance therapy in myeloma patients
-
2:21
overview of the tourmaline-mm1 study in relapsed/refractory multiple myeloma
-
6:07
ixazomib plus pomalidomide, dexamethasone in relapsed/refractory myeloma
-
4:48
overview of the final analysis of the phase iii tourmaline-mm1 trial
-
2:21
tourmaline-mm1 study produces optimistic results for mm
-
1:49
real world data of ixazomib in combination with lenalidomide and dexamethasome
-
7:11
final analysis of the phase 3 tourmaline-mm1: ixazomib lenalidomide-dex vs placebo-rd in rrmm
-
2:36
what does the tourmaline-mm2 study tell us about the use of ixazomib in multiple myeloma?
-
1:12
dr. kumar on tourmaline-mm1 study for multiple myeloma
-
7:15
endeavour, aspire and tourmaline-mm1 trial results for multiple myeloma
-
2:54
tourmaline-mm4: oral ixazomib maintenance for myeloma
-
4:20
ixazomib or lenalidomide post-asct in ndmm
-
1:22
long-term follow-up results of tourmaline-mm2: ird vs pbo-rd in multiple myeloma
-
5:29
tourmaline-mm1: benefit of ird triplet for r/r mm
-
1:26
evaluating the efficacy of ixazomib, cyclophosphamide and dexamethasone in amyloidosis
-
2:36
first all-oral treatment for relapsed and treatment-resistant multiple myeloma
-
0:58
the efficacy of ixazomib for the treatment of r/r myeloma
-
8:32
any role for maintenance ixazomib in multiple myeloma? - medpage today